Evidence map›Paper›PMID 36578271›Full record

ArticleExtracellular vesicle2022

Cell-derived nanovesicles prepared by membrane extrusion are good substitutes for natural extracellular vesicles.

Yi Wen, Qin Fu, Ashley Soliwoda, Sheng Zhang, Mingfeng Zheng, Wenjun Mao, Yuan Wan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Extracellular vesicle, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed.

  1. Article
  2. Hypothalamic wars: the last nanodelivery.Reviews in endocrine & metabolic disorders · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Exosomes and Exosome-Mimetics for Atopic Dermatitis Therapy.Tissue engineering and regenerative medicine · 2025
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi WenThe Pq Laboratory of BiomeDx/Rx, Department of Biomedical Engineering, Binghamton University, Binghamton, NY 13902, USA.
Qin FuProteomics & Metabolomics Facility, Cornell Institute of Biotechnology, Cornell University, Ithaca, NY 14853, USA.
Ashley SoliwodaThe Pq Laboratory of BiomeDx/Rx, Department of Biomedical Engineering, Binghamton University, Binghamton, NY 13902, USA.
Sheng ZhangProteomics & Metabolomics Facility, Cornell Institute of Biotechnology, Cornell University, Ithaca, NY 14853, USA.
Mingfeng ZhengDepartment of Cardiothoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Jiangsu 214023, China.
Wenjun MaoDepartment of Cardiothoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Jiangsu 214023, China.
Yuan WanThe Pq Laboratory of BiomeDx/Rx, Department of Biomedical Engineering, Binghamton University, Binghamton, NY 13902, USA.

Funding

Liquid biopsy of solitary pulmonary nodule with extracellular vesiclesR37CA255948 · NCI · STATE UNIVERSITY OF NY,BINGHAMTON · PI Yuan Wan · 2021 to 2026
$3.0M
Lipid nanoprobe integrated microdevice for extracellular vesicle isolation and duplex sequencing based mutation detection for non-invasive lung cancer diagnosisR01CA230339 · NCI · PENNSYLVANIA STATE UNIVERSITY, THE · PI ZHENG, SIYANG · 2018 to 2023
$1.9M
Acquisition of a Hybrid Quadrupole Time of Flight LC-MS/MS System for the CornellS10OD017992 · OD · CORNELL UNIVERSITY · PI ZHANG, SHENG · 2014 to 2014
$600k
NCI NIH HHS R01 CA230339NCI NIH HHS R37 CA255948NIH HHS S10 OD017992
6 · The paper itself

Abstract

Extracellular vesicles (EV) as drug delivery nanocarriers are under intense investigation. Although clinical-grade EVs have been produced on a large-scale, low yield and high production costs of natural EVs (nEV) limit the relevant industrial translation. Recent studies show that mechanical extrusion of cells can generate nEV-like cell-derived nanovesicles (CNV) which can also be used as drug nanocarriers. Moreover, in comparison with nEVs, CNVs have similar physicochemical properties. Nevertheless, a comprehensive comparison of cargo between nEVs and CNVs has not been investigated yet. Therefore, the aim of this study is to profile and compare CNVs to nEVs. Our results show that no significant difference was found in size, morphology, and classical markers between nEVs and CNVs derived from MDA-MB-231 cells. Protein sequencing data reveals the similarity of membrane proteins between the two groups was ~71%, while it was ~21% when pertaining to total protein cargo. Notably, a high similarity of membrane proteins was also found between nEVs and CNVs derived from eight additional cancer cell lines. Moreover, analysis of the top 1000 small RNAs with RNA sequencing showed a ~65% similarity between the two groups. Altogether, we infer from the high similarity of membrane proteins and small RNA cargo that CNVs can be a good substitute for nEVs. In brief, our findings support previous studies with a notion that CNVs yield comparable performance with nEVs and could pave the way for clinical implementation of CNV-based therapeutics in the future.

Indexed as

Cell engineered vesiclesDrug deliveryExtracellular vesiclesMass spectrometryNext-generation sequencing

Identifiers

PMID36578271
PMCPMC9794200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.